Shanghai-based cell therapy biotech nabs new funds; Colorado biotech nets an acquisition – Endpoints News

Shanghai-based cell therapy biotech nabs new funds; Colorado biotech nets an acquisition – Endpoints News

  • Funds
  • September 2, 2022
  • No Comment
  • 4

A Lil­ly Asia Ven­tures-backed cell ther­a­py biotech has se­cured $50 mil­lion in Se­ries A funds to bankroll CAR-NK ther­a­pies.

At the helm of the Shang­hai-based Neukio Bio­ther­a­peu­tics is a leader with ex­pe­ri­ence in the CAR-T cell ther­a­py mar­ket, with Richard Liqun Wang hav­ing pre­vi­ous­ly served as chief ex­ec­u­tive of the Fo­s­un and Kite joint ven­ture that land­ed the first CAR-T cell ther­a­py ap­proval in Chi­na last year. Kite and own­er Gilead mar­ket the cell ther­a­py prod­uct as Yescar­ta in the US.

Neukio raised the round with sup­port from Lil­ly Asia Ven­tures, Sher­pa Health­care Part­ners and IDG Cap­i­tal. The com­pa­ny pre­vi­ous­ly snagged $40 mil­lion in what it char­ac­ter­ized as an an­gel round in Oc­to­ber 2021. The same in­vestors took part in that fi­nanc­ing.

The biotech, formed last year, is look­ing to make al­lo­genic cell ther­a­pies “via the iP­SC-CAR-NK ax­is,” ac­cord­ing to its web­site. Neukio has 5,700 square me­ters of R&D and man­u­fac­tur­ing space, the biotech says on its web­site.

With the Se­ries A, Neukio said it will put can­di­dates through pre­clin­i­cal and clin­i­cal stud­ies, as well as use the pro­ceeds to hire more em­ploy­ees.

“In as lit­tle as 10 months since the op­er­a­tion of our new lab­o­ra­to­ries, not on­ly have we com­plet­ed sev­er­al sig­nal­ing path­way mod­i­fi­ca­tions and CAR de­signs tai­lored for sol­id tu­mors, but al­so we have made sig­nif­i­cant progress in the de­vel­op­ment of in­no­v­a­tive man­u­fac­tur­ing process­es of NK dif­fer­en­ti­a­tion and ex­pan­sion,” Wang, the founder, CEO and chair­man, said in a state­ment.

New in­vestors in­clude CD Cap­i­tal, Al­win Cap­i­tal and Sur­plus Cap­i­tal. — Kyle LaHu­cik

Flag­ship Bio­sciences ac­quire a di­vi­sion from In­ter­pace  

A Col­orado-based biotech is look­ing to snap up a di­vi­sion from In­ter­pace Bio­sciences.

Flag­ship Bio­sciences, which pro­vides bi­o­log­i­cal and bio­mark­er an­a­lyt­i­cal ser­vices, has ac­quired In­ter­pace Phar­ma So­lu­tions, a di­vi­sion of In­ter­pace Bio­sciences, for an undis­closed amount.

Ac­cord­ing to Flag­ship, the com­bined com­pa­ny will add to an ar­se­nal of an­a­lyt­i­cal and bio­mark­er ser­vices as well as pro­vide ac­cess to a re­search lab­o­ra­to­ry in North Car­oli­na’s Re­search Tri­an­gle.

“By com­bin­ing these or­ga­ni­za­tions, we cre­ate a sin­gle-source provider of­fer­ing a larg­er range of bio­mark­er and an­a­lyt­ics ser­vices while main­tain­ing and ex­pand­ing the proven ex­per­tise of each lab­o­ra­to­ry,” said Trevor John­son, Flag­ship’s CEO in a state­ment.

The deal, ac­cord­ing to Flag­ship, aims to use IPS’s ca­pa­bil­i­ties to sup­port clin­i­cal tri­als and di­ag­nos­tic de­vel­op­ment in sev­er­al ar­eas in­clud­ing im­muno-on­col­o­gy, hema­tol­ogy and sol­id tu­mors, among oth­ers.

This ac­qui­si­tion al­so comes on the back of Flag­ship re­ceiv­ing an in­vest­ment from Am­per­sand Cap­i­tal Part­ners, BroadOak Cap­i­tal Part­ners and Re­search Cor­po­ra­tion Tech­nolo­gies. The amount of the in­vest­ment was not dis­closed. — Tyler Patchen

Source link

Related post

Healthium Medtech amongst the first in Asia and first…

– Meets highest safety and quality standards as a medical devices manufacturer Amongst the first medtech companies in Asia to receive…
Montgomery County funds upgrades for Canajoharie park

Montgomery County funds upgrades for Canajoharie park

VILLAGE OF CANAJOHARIE — Upgrades including a new pavilion and playground are slated for Wintergreen Park in the village of Canajoharie…
The Fiji Times » Bitcoin scam

The Fiji Times » Bitcoin scam

The Fiji Financial Intelligence Unit (FIU) says there are currently no authorised virtual assets service providers in Fiji. It made this…

Leave a Reply

Your email address will not be published.